Internal Medicine, Hematology & Oncology · Orlando, FL
NPI
1891946646
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
9430 Turkey Lake Rd
Orlando, FL, 32819
Phone (407) 648-3800
Groups this clinician bills Medicare through
Medicare paid, 2024
$50K
532 services
Medicare patients, 2024
238
Average age 75
Drug cost, 2024
$5.2M
1,167 prescriptions
Company payments, 2025
$3,795
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sreeram Maddipatla was code 99214 (office e&m - established), 204 times for 126 patients. In total Sreeram Maddipatla billed 532 services in 7 codes, and Medicare paid $50K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-06-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 204 | 126 | $66.16 | $13K |
| 99215 Office E&M - Established | Facility | 188 | 85 | $108.10 | $20K |
| 99223 Hospital E&M - Initial | Facility | 66 | 61 | $130.62 | $8,621 |
| 99205 Office E&M - New | Facility | 29 | 29 | $137.09 | $3,976 |
| 99232 Hospital E&M - Subsequent | Facility | 26 | 19 | $61.39 | $1,596 |
By year: 2022 $53K for 548 services; 2023 $48K for 592 services; 2024 $50K for 532 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sreeram Maddipatla prescribed most often to Medicare patients was Eliquis (Apixaban), with 126 prescriptions and refills. In total Sreeram Maddipatla wrote 1,167 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 126 | 181 | 34 | $104K |
| Prochlorperazine Maleate Generic | 74 | 74 | 41 | $1,145 |
| Revlimid Lenalidomide | 70 | 70 | Under 11 | $967K |
| Ondansetron Hcl Generic | 65 | 69 | 41 | $2,896 |
| Erleada Apalutamide | 63 | 63 | Under 11 | $917K |
| Xtandi Enzalutamide | 36 | 36 | Under 11 | $508K |
| Acyclovir Generic | 32 | 46 | 14 | $308 |
| Prednisone Generic | 31 | 31 | 11 | $113 |
| Abiraterone Acetate Generic | 30 | 30 | Under 11 | $54K |
| Nubeqa Darolutamide | 30 | 30 | Under 11 | $398K |
| Letrozole Generic | 28 | 45 | Under 11 | $669 |
| Warfarin Sodium Generic | 27 | 49 | Under 11 | $112 |
| Hydroxyurea Generic | 27 | 59 | Under 11 | $949 |
| Imatinib Mesylate Generic | 26 | 26 | Under 11 | $12K |
| Everolimus Generic | 25 | 25 | Under 11 | $23K |
Brand drugs: 512 claims; generic drugs: 655 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sreeram Maddipatla $3,795 ($3,795 in general payments such as food, travel and fees) from 4 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $3,078.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.